Clinical Trial Update: A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine [Phase 2]

View source ↗

Summary

Phase IIb open-label, dose-ranging study of the 13-valent pneumococcal conjugate vaccine in adults 55-74 previously vaccinated with PPSV23; study completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (PCV13) (pneumococcal conjugate vaccine, 13-valent)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Pneumococcal Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-01-23